Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the ...

Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet April 20, 2026 11:00 AM ...

(Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment ...

Amgen has struck a deal with Entera Bio to develop oral formulations of up to three large molecules. The agreement sees Amgen pay a “modest” upfront fee to access Entera’s technology and commit to up ...

Shares of Entera Bio Ltd. ENTX surged 44.7% after it announced positive bone mineral density (BMD) results at six months from the completed phase II study on pipeline candidate, EB613, for the ...

The Dow Jones gained by over 50 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around ...

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with ...

JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that ...

Amgen has ended its alliance with Entera Bio. The partners entered into a $270 million, three-molecule deal in 2018 but have agreed to scuttle the collaboration before reaching any major milestones.